Related Experiment Video

Updated: Mar 21, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Progress in the mechanism and drug development of castration-resistant prostate cancer

Minzan Zuo1, Xi Xu1, Tinghan Li1

  • 1Department of Medicinal Chemistry, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing 210009, PR China.

Future Medicinal Chemistry
|May 6, 2016
PubMed

Insights

Castration-resistant prostate cancer (CRPC) inevitably develops after initial treatment. This review covers CRPC mechanisms, novel therapies like sipuleucel-T and enzalutamide, and future research needs.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Prostate cancer often progresses to a castration-resistant state despite androgen deprivation therapy.
  • Understanding CRPC mechanisms is crucial for developing new treatments.

Purpose of the Study:

  • To review the mechanisms driving castration-resistant prostate cancer (CRPC).
  • To discuss the development and clinical application of novel CRPC therapeutic agents.
  • To highlight ongoing challenges and future research directions in CRPC treatment.

Main Methods:

  • Literature review of mechanisms and therapies for castration-resistant prostate cancer.
  • Analysis of novel agents including immunomodulators, androgen receptor antagonists, chemotherapy, and radiopharmaceuticals.
  • Discussion of clinical advancements and therapeutic challenges.

Main Results:

  • Several novel agents have emerged for CRPC, including sipuleucel-T, enzalutamide, docetaxel, and radium-223.
  • These agents target different pathways involved in CRPC progression.
  • The review synthesizes current understanding of CRPC mechanisms and therapeutic strategies.

Conclusions:

  • Despite advances, CRPC remains a significant clinical challenge.
  • Identifying predictive biomarkers and optimizing combination therapies are key future goals.
  • Further research is essential for a comprehensive understanding and improved management of CRPC.
Keywords:
androgen receptor antagonistscastration-resistant prostate cancercross-resistancepredictive biomarkersprostate-specific antigentreatment strategies

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.1K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K